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Be Aware of the new European Society of Cardiology Atrial Fibrillation Guidelines during 
Global Atrial Fibrillation Aware Week 
Atrial Fibrillation (AF) the most common cardiac arrhythmia is associated with a five-fold increased 
risk of stroke (Menke et al, 2010). AF-related stroke is more likely to be fatal or severely disabling 
compared to other types of stroke because clots that form in the heart are large and can obstruct 
large vessels in the brain. During November, the Atrial Fibrillation Association Global AF Aware week 
will focus national attention to 1) detecting AF, 2) protecting those with AF from stroke using 
anticoagulation therapy, 3) correcting irregular rhythms using appropriate treatments and 4) perfecting 
the patient pathway. Increased clinical understanding and knowledge of recent guidelines by 
healthcare professionals are necessary to ensure integrated care for those diagnosed or suspected of 
having AF.   
Prevalence of AF is increasing and is predicted to double by 2050 (Schnabel et al, 2015), leading to 
costly and complex hospital admissions and reduced quality of life. Estimates suggest around 1.2 
million people in the UK have a diagnosis of AF (Stroke Association, 2017), with a further half million 
people currently undiagnosed. Incidence increases with age and those ≥ 85yrs are seven times more 
likely to have AF compared with those <55yrs (Lane et al, 2017). Other risk factors include diabetes, 
ethnicity, hypertension, obesity, obstructive sleep apnoea and congestive heart failure. Although it is 
possible to develop AF without other health conditions, incidence is higher in complex comorbid 
populations. 
Public Health England have declared that stroke prevention in AF is a national priority. 
Anticoagulation is a preventative treatment that reduces AF-related stroke risk by two-thirds. In fact, if 
AF were adequately identified and treated around 7000 strokes could be prevented every year, saving 
approximately 2000 lives (Stroke Association, 2017). AF is greatly associated with heart failure, in 
part because both conditions have shared mechanisms, leading to neurohormonal and 
proinflammatory activation, which can induce myocardial inflammation and fibrosis (Staerk et al, 
2017). Equally, AF has also been shown to be an independent risk factor for cognitive decline and 
dementia. Symptoms such as palpitations, breathlessness and fatigue affect up to 80% of individuals 
(Go et al, 2001) and psychological distress is reported in 35%, potentially due to the unpredictable 
nature of symptoms or fear of future thromboembolic event (Walters et al, 2018). Management is 
complex and attention must be given to the complete patient experience. 
Updated European Society of Cardiology guidelines  
In August 2020, new European Society of Cardiology (ESC) AF guidelines (Hindricks et al, 2020) 
were released and firstly suggest confirmation and characterisation (CC) of condition, followed by 
‘Atrial fibrillation Better Care’ (CC-ABC) pathway to manage AF (Figure 1). This includes three 
elements; A-Avoid Stroke, B-Better symptom management, and C-Cardiovascular risk reduction. This 
approach, which is driven by a strong interdisciplinary team, is associated with reductions in all-cause 
hospitalisation and all-cause death (Proietti et al, 2020) equating to lower healthcare costs and better 
patient outcomes.  
Following the new guidelines, CONFIRMATION helps to frame the decision to screen or not to 
screen. Identification (confirmation) of AF enables early treatment and potentially improves prognosis 
but it is unclear what screening works, for whom, and in what circumstances. Current ESC 
recommendations support opportunistic screening for those ≥ 65 years whilst systematic screening 
should be considered to detect AF in individual’s ≥ 75 years, or those at high risk of stroke (Hindricks 
et al, 2020). Of importance, screening programmes must be linked to ongoing management pathways 
to be effective. CHARACTERISATION highlights a key change in thinking, suggesting that focus 
should be on structured characterisation not classification of AF. AF is widely categorised using the 
3Ps (paroxysmal, persistent/long-standing persistent, and permanent AF), which describe type of AF 
based on the duration of the arrhythmia and its mode of termination. Labelling AF in this way fails to 
capture comprehensively the multifaceted, individualised lived experience of each AF case. The ESC 
recommends characterisation based on clinical assessment of stroke risk, symptom status, burden of 
AF, and evaluation of electrophysiological and structural properties of the atrium (substrate severity). 
Once AF has been confirmed and characterised, the next step is AVOID STROKE ensuring adequate 
anticoagulation for those at risk of stroke. All AF patients should be assessed for their stroke risk 
using a CHA2DS2–VASc score (Figure 2) and everyone not at low risk (CHA2DS2-VASc score = 0 in 
men, or 1 in women) should be offered anticoagulation. However, 34% of those with a CHA2DS2–
VASc ≥ 2, have been reported not to be anticoagulated without a documented record of clinical 
contraindication to anticoagulation therapy or patient refusal (Cowan et al, 2013). Additionally, despite 
demonstrable benefits, systematic review indicates 30% of patients are non-adherent to their 
prescribed anticoagulation medication (Salmasi et al, 2020).  Further studies are needed to increase 
understanding of non-adherence patterns to improve targeting the right patients at the right time with 
the right intervention to increase medication adherence. Adherence will also help achieve BETTER 
SYMPTOM CONTROL. First line treatment to improve AF symptom burden is pharmaceutical rate 
and rhythm control. During asymptomatic periods of AF, when patients perhaps feel well, there is a 
risk of non-adherence to medication. Shared decision making during treatment consultations could 
improve patient perceptions on when and for how long they must continue treatment. The ESC 
guidelines recommend ongoing review of patient reported symptoms to measure treatment success 
and maintain patient engagement with their care plan. Finally, the guidelines highlight the importance 
of CONTROL of CARDIOVACULAR RISK.  Management plans should focus on reducing 
cardiovascular risk factors such as hypertension, physical inactivity and obesity in those with AF. 
Many people diagnosed with AF are unaware of the link between unhealthy lifestyle risk factors and 
AF symptom severity and potential disease progression. The challenge for healthcare professionals is 
to design and implement AF interventions that emphasise self-management to promote patients to not 
only increase their adherence to medication but to take a more active role in managing their own 
condition. 
Interventions for atrial fibrillation care 
It is possible to support self-management through patient education or developing a programme that 
includes specific behaviour change techniques (e.g. goal setting or symptom tracking) to encourage 
long-lasting lifestyle changes. Nurse-led AF clinics and telehealth interventions are examples of how 
healthcare systems have responded to ESC recommendations that AF care must be multidisciplinary 
in approach. Speciality nurse led clinics reduce wait times to be seen, get diagnosed and to receive 
hospital based treatment. They are associated with reduced rates of hospitalisations and overall 
healthcare costs (Rush et al, 2019). Telehealth interventions are a now well-accepted method of 
delivering care remotely in a patient’s own environment. In terms of AF, telehealth offers tools to 
educate, monitor symptoms, track medication and physiological measurements, and enable reminder 
functions to increase medication adherence (Kotecha et al, 2017). During the ongoing COVID-19 
pandemic proactive use of telehealth could improve patient access to healthcare and support whilst 
also mitigating some of the negative effects from social isolation. Telecheck-AF, an international 
initiative enrolling nearly 2000 patients across 37 European centres, is one such scheme. The 
technology is able to transform a smartphone into a rate-and-rhythm detector to provide real-time 
patient physiological measurements from which healthcare professionals can make informed remote 
clinical decisions to ensure continuity of AF care during uncertain times. 
As Atrial Fibrillation Association Global AF Aware week approaches, we have the opportunity to 
ensure that AF services remain streamlined despite COVID-19. It is important clinicians familiarise 
themselves with updated guidelines and that we continue to think outside of the box to provide 
ongoing holistic clinical and psychological support remotely for those diagnosed or suspected of 
having AF. 








Figure 2. CHA2DS2–VASc Score adapted from ESC 2020  
 
Risk Factors  Points  
Congestive heart failure +1 
Hypertension +1 
Age 75 years or older +2 
Diabetes mellitus +1 
Stroke +2 
Vascular disease +1 
Age 65-75 years +1 
Sex category (female) +1 
Maximum score = 9 
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